Evidence map›Paper›PMID 35127508›Full record

ArticleFrontiers in oncology2021

The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis.

Angeliki Andrikopoulou, Spyridoula Chatzinikolaou, Ilias Kyriopoulos, Garyfalia Bletsa, Maria Kaparelou, Michalis Liontos, Meletios-Athanasios Dimopoulos, Flora Zagouri

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Selenium-Containing Compounds in Breast Cancer Therapy.Biological trace element research · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Angeliki AndrikopoulouDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
Spyridoula ChatzinikolaouDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
Ilias KyriopoulosDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
Garyfalia BletsaHellenic Anticancer Institute, Athens, Greece.
Maria KaparelouDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
Michalis LiontosDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
Meletios-Athanasios DimopoulosDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
Alexandra Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAround 5%-7% of breast cancer cases are diagnosed in women younger than 40, making it the leading cause of female cancer in the 25- to 39-year-old age group. Unfortunately, young age at diagnosis is linked to a more aggressive tumor biology and a worse clinical outcome. The identification of the mutational landscape of breast cancer in this age group could optimize the management.

methodsWe performed NGS analysis in paraffin blocks and blood samples of 32 young patients with breast cancer [<40 years] and 90 older patients during the period 2019 through 2021. All patients were treated in a single institution at the Oncology Department of "Alexandra" Hospital, Medical School, University of Athens, Greece.

resultsBreast tumors were characterized more frequently by HER2 overexpression [25% vs 18.9%], higher ki67 levels [75% vs 61%] and lower differentiation [71.9% vs 60%] in the younger group. PIK3CA [6/20; 30%] and TP53 [6/20; 30%] were the most frequent pathogenic somatic mutations identified in young patients, while one case of BRCA2 somatic mutation [1/20; 5%] and one case of PTEN somatic mutation [1/20; 5%] were also identified. PIK3CA mutations [16/50; 32%] and TP53 mutations [20/50; 40%] were the most common somatic mutations identified in older patients, however other somatic mutations were also reported (ATM, AKT, CHEK2, NRAS, CDKN2A, PTEN, NF1, RB1, FGFR1, ERBB2). As for germline mutations, CHEK2 [3/25; 12%] was the most common pathogenic germline mutation in younger patients followed by BRCA1 [2/25; 8%]. Of note, CHEK2 germline mutations were identified less frequently in older patients [2/61; 3%] among others [BRCA1 (2/61; 3%), ATM (2/61; 3%), APC (1/61; 1,6%) and BRCA2 (1/61; 1,6%)].

conclusionWe here report the mutational profile identified

Indexed as

breast cancerearly-onsetgenetic testingNGSyoung women

Identifiers

PMID35127508
PMCPMC8813959
OpenAlexW4206575173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.